Anti–PD-1/PD-L1 mAbs are able to block the binding between PD-1 and PD-L1 to revert immunosuppressive signals by cancer cells and to enhance immune cells activity in the elimination of malignant cells (113). This evidence concerns the gene PDCD1 and cancer.